Intralesional PV-10 for in-transit melanoma—A single-center experience
详细信息 查看全文
- 作者：Jocelyn Lippey ; Rhiannon Bousounis ; Cori Behrenbruch ; Bartholomew McKay ; John Spillane ; Michael A. Henderson ; David Speakman and David E. Gyorki
- 刊名：Journal of Surgical Oncology
- 出版年：2016
- 出版时间：September 1, 2016
- 年：2016
- 卷：114
- 期：3
- 页码：380-384
- 全文大小：3292K
- ISSN：1096-9098
文摘
Patients with in-transit melanoma metastasis have longer median survival than patients with distant metastatic disease. Furthermore, local disease control is an important endpoint for symptom management. The treatment of unresectable loco-regional recurrence or in-transit disease has been historically managed with a combination of treatments including surgery, radiotherapy, isolated limb infusion or perfusion as well as systemic therapies. Intralesional PV-10 has been used at Peter MacCallum Cancer Centre since 2010, and the current report presents a retrospective analysis of patient outcomes, reporting the response rates, durability of responses, and observed toxicities.